Elixinol Wellness Ltd · ASX:EXL
Elixinol Wellness — Shareholder Meeting (May 2024)
17 slides from Elixinol Wellness's shareholder meeting presentation, May 30, 2024
Slide 1: Annual General Meeting May 2024
Annual General Meeting May 2024
Slide 2: Disclaimer
Disclaimer The following material is for general information purposes only and should not be relied on for the making of any investment decision. Any investment in Elixinol Wellness Limited ACN 621 479 794 (Elixinol Wellness) is subject to a number of investment risks including the possibility of lo
Slide 3: Chairman's Address
Chairman’s Address Annual General Meeting 3
Slide 4: Elixinol Wellness 2023 Overview
Elixinol Wellness 2023 Overview TSN Acquisition Cost Reduction Sales Growth The merger with TSN was completed The substantial cost reductions of Organic sales growth across our successfully, and the collaboration 30% have established a solid leading brands and hemp ingredients between the businesses
Slide 5: Financial Highlights 2023
Financial Highlights 2023 • 51% Growth in Australian Revenues: A key market, boosted by the TSN merger in August 2024 and a 25% increase in B2C sales of Hemp Foods Australia products. • 21% Decline in Elixinol Americas eCommerce Revenues: Reflects a challenging market with an unclear regulatory path
Slide 6: A New Era for Elixinol Wellness
A New Era for Elixinol Wellness Board of Directors DAVE FENLON PAULINE GATELY NATALIE BUTLER INDEPENDENT CHAIR AND NON-EXECUTIVE DIRECTOR NON-EXECUTIVE DIRECTOR EXECUTIVE DIRECTOR / MARKETING • Over 30 years’ experience in FMCG and • Extensive Board experience in FMCG, mining, • Over a decade of str
Slide 7: A New Era for Elixinol Wellness
A New Era for Elixinol Wellness As we forge ahead in a new era for Elixinol Wellness, we are focused on building a profitable business around our house of brands tailored to the future needs of consumers. What Sets Us Apart: • Emphasis on natural, nutrient-rich, and clean-label products. • Alignment
Slide 8: A New Era for Elixinol Wellness
A New Era for Elixinol Wellness HEMP FOODS AUSTRALIA MT. ELEPHANT ELIXINOL USA FIELD DAY Plant-based nutrition and Wholefood baking mixes CBD-focused Wholefood Pet wellness products for healthy indulgence Nutraceuticals Supplements Annual General Meeting 8
Slide 9: A New Era for Elixinol Wellness
A New Era for Elixinol Wellness Healthy plant-based products for everyone, every day Human Nutrition Ingredients: Shared Synergies driving a revolution in plant-based Hemp Hemp Foods Mt Elephant health and wellness products & ingredients Australian Primary Hemp Soul Seeds Hemp Foods Ananda Foods Pet
Slide 10: Q1 FY24 Key Highlights
Q1 FY24 Key Highlights Adjusted EBITDA improvement and 6th Qtr. of revenue growth • Compelling Q1 FY24 performance. 6th consecutive quarter of revenue growth. Group revenue up 76% to $3.0M from $1.7M a year ago. • Expanded brand portfolio delivering impressive results. Australian revenue jumped 140%
Slide 11: Harnessing the Power of Hemp
Harnessing the Power of Hemp Acquisition of Ananda Food confirms Elixinol Wellness as the undisputed leader in the Australian Hemp Market, leveraging hemp’s immense potential as a "future food" and a sustainable crop. MARKET DOMINANCE RETAIL DISTRIBUTION Annual General Meeting 11
Slide 12: Brand Highlights
Brand Highlights 12
Slide 13: Mt. Elephant Highlights
Mt. Elephant Highlights • Expanded Ranging in Woolworth in Q2 FY23 • Expanded national distribution into Coles in 2024 • Strong growth of base by 25% q-o-q • Tracking above category average in both loyalty and eComm • Three new products launched in Q2 FY23 Mt Elephant Sales Annual General Meeting 13
Slide 14: Hemp Foods Highlights
Hemp Foods Highlights • Gold Oil expanded Woolworths ranging in Jan 2023 • Sales progress driven by organic growth in protein business • Launched TGA Omega Oil Caps in Q3 FY23 HFA Sales Gold Protein Sales Annual General Meeting 14
Slide 15: Elixinol USA Highlights
Elixinol USA Highlights • FY23: $2.64 million revenue despite regulatory challenges. • Stable eCommerce Revenue: Servicing and subscription orders contributed one-third of eCommerce revenue. • Lean Operations: Poised for positive FY24 EBITDA contribution Elixinol Sales Annual General Meeting 15
Slide 16: Positioned for Strong Future Growth
Positioned for Strong Future Growth Market Leadership Operational Efficiency • With two significant mergers and acquisitions finalised, • Sales and operational synergies propel the path towards Elixinol has become the unparalleled leader in profitability and a sustainable business model. Australia's
Slide 17: Thank you!
Elixinol © Wellness Thank you!